IL249587A0 - Heterocyclic carboxylic acids as activators of soluble guanylate cyclase - Google Patents

Heterocyclic carboxylic acids as activators of soluble guanylate cyclase

Info

Publication number
IL249587A0
IL249587A0 IL249587A IL24958716A IL249587A0 IL 249587 A0 IL249587 A0 IL 249587A0 IL 249587 A IL249587 A IL 249587A IL 24958716 A IL24958716 A IL 24958716A IL 249587 A0 IL249587 A0 IL 249587A0
Authority
IL
Israel
Prior art keywords
quanylate
cyclase
activators
soluble
carboxylic acids
Prior art date
Application number
IL249587A
Other languages
English (en)
Hebrew (he)
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53783363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL249587(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of IL249587A0 publication Critical patent/IL249587A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
IL249587A 2014-07-22 2016-12-15 Heterocyclic carboxylic acids as activators of soluble guanylate cyclase IL249587A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462027376P 2014-07-22 2014-07-22
PCT/US2015/041245 WO2016014463A1 (en) 2014-07-22 2015-07-21 Heterocyclic carboxylic acids as activators of soluble guanylate cyclase

Publications (1)

Publication Number Publication Date
IL249587A0 true IL249587A0 (en) 2017-02-28

Family

ID=53783363

Family Applications (1)

Application Number Title Priority Date Filing Date
IL249587A IL249587A0 (en) 2014-07-22 2016-12-15 Heterocyclic carboxylic acids as activators of soluble guanylate cyclase

Country Status (26)

Country Link
US (1) US9353090B2 (OSRAM)
EP (1) EP3172202B1 (OSRAM)
JP (1) JP6602840B2 (OSRAM)
KR (1) KR20170035993A (OSRAM)
CN (1) CN106459017B (OSRAM)
AP (1) AP2016009615A0 (OSRAM)
AR (1) AR101265A1 (OSRAM)
AU (1) AU2015292833B2 (OSRAM)
BR (1) BR112017000943A2 (OSRAM)
CA (1) CA2955937A1 (OSRAM)
CL (1) CL2017000071A1 (OSRAM)
CO (1) CO2017000438A2 (OSRAM)
DK (1) DK3172202T3 (OSRAM)
EA (1) EA032972B1 (OSRAM)
ES (1) ES2784477T3 (OSRAM)
HU (1) HUE049231T2 (OSRAM)
IL (1) IL249587A0 (OSRAM)
MX (1) MX378717B (OSRAM)
PE (1) PE20170249A1 (OSRAM)
PH (1) PH12017500111A1 (OSRAM)
PL (1) PL3172202T3 (OSRAM)
PT (1) PT3172202T (OSRAM)
SG (2) SG10201806565SA (OSRAM)
TW (1) TWI711615B (OSRAM)
UY (1) UY36226A (OSRAM)
WO (1) WO2016014463A1 (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7098214B2 (ja) * 2016-02-01 2022-07-11 サイクレリオン・セラピューティクス，インコーポレーテッド 非アルコール性脂肪性肝炎（ＮＡＳＨ）の処置のためのｓＧＣ刺激物質の使用
US10570074B2 (en) 2016-09-14 2020-02-25 Genomatica, Inc. 1,3-fatty diol compounds and derivatives thereof
EP3525778A1 (de) 2016-10-11 2019-08-21 Bayer Pharma Aktiengesellschaft Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten
CN106495999B (zh) * 2016-10-18 2019-08-16 亳州学院 一种芳香醛及其合成方法
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
CN110891954A (zh) 2017-07-14 2020-03-17 葛兰素史密斯克莱知识产权发展有限公司 富含亮氨酸的重复激酶2的抑制剂
US12065396B2 (en) * 2017-08-17 2024-08-20 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
EP3498298A1 (en) 2017-12-15 2019-06-19 Bayer AG The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi)
US20210230155A1 (en) * 2018-04-27 2021-07-29 Hetero Labs Limited Process for preparation of ((3r,11br)-1,3,4,6,7,11b-hexahydro-9,10-di(methoxy-d3)-3-(2-methylpropyl)-2h-benzo[a]quinolizin-2-one
EP3787610A1 (en) 2018-04-30 2021-03-10 Bayer Aktiengesellschaft The use of sgc activators and sgc stimulators for the treatment of cognitive impairment
CN112384213A (zh) 2018-05-15 2021-02-19 拜耳公司 用于治疗与神经纤维敏化有关的疾病的1,3-噻唑-2-基取代的苯甲酰胺
US11508483B2 (en) 2018-05-30 2022-11-22 Adverio Pharma Gmbh Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group
WO2020117493A1 (en) 2018-12-03 2020-06-11 Fmc Corporation Method for preparing n-phenylpyrazole-1-carboxamides
US20220128561A1 (en) 2019-01-17 2022-04-28 Bayer Aktiengesellschaft Methods to determine whether a subject is suitable of being treated with an agonist of soluble gyanylyl cyclase (sgc)
CN114206852A (zh) 2019-08-09 2022-03-18 卡尔维斯塔制药有限公司 血浆激肽释放酶抑制剂
AU2021308681A1 (en) 2020-07-16 2023-03-09 Acuitas Therapeutics, Inc. Cationic lipids for use in lipid nanoparticles
CN114957087A (zh) * 2022-04-13 2022-08-30 湖南复瑞生物医药技术有限责任公司 一种帕罗韦德中间体制备方法
EP4536205A1 (en) 2022-06-09 2025-04-16 Bayer Aktiengesellschaft Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067938A1 (en) 2000-09-29 2004-04-08 Penglie Zhang Quaternary amines and related inhibitors of factor xa
BRPI0614001A2 (pt) 2005-07-18 2011-03-01 Bayer Healthcare Ag uso de ativadores e estimuladores de guanilato ciclase solúvel para a prevenção ou tratamento de distúrbios renais
US20080045560A1 (en) 2006-08-15 2008-02-21 Wyeth Pyrrolidine and related derivatives useful as PR modulators
BRPI0811581A2 (pt) 2007-05-12 2014-12-09 Bayer Schering Pharma Ag Estimuladores de sgc, ativadores de sgc e combinações para o tratamento de distúrbios urológicos
CA2698332C (en) 2007-09-06 2012-08-21 Merck Sharp & Dohme Corp. Pyrazole derivatives as soluble guanylate cyclase activators
WO2009043495A1 (en) 2007-10-05 2009-04-09 Sanofi-Aventis Deutschland Gmbh Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid n-phenylamides in the treatment of pain
WO2009068652A1 (en) 2007-11-30 2009-06-04 Smithkline Beecham Corporation 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators
AR069517A1 (es) 2007-12-03 2010-01-27 Smithkline Beecham Corp Compuesto del acido fenil metiloxifenil piridinil carboxilico substituido, composiciones farmaceuticas que lo comprenden y su uso para la prepara-cion de un medicamento util para el tratamiento de una enfermedad mediada por la actividad de la enzima sgc
WO2009123316A1 (ja) 2008-04-04 2009-10-08 武田薬品工業株式会社 複素環誘導体及びその用途
WO2010015653A1 (en) 2008-08-07 2010-02-11 Smithkline Beecham Corporation Pyrimidine derivatives as activators of soluble guanylate cyclase
WO2010015652A2 (en) 2008-08-07 2010-02-11 Smithkline Beecham Corporation Thiazole compounds as activators of soluble guanylate cyclase
EP2373317B1 (en) 2008-11-25 2016-12-14 Merck Sharp & Dohme Corp. 4-amino-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one or 4-amino-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one derivatives as activators of the soluble guanylat cyclase for the treatment of cardiovascular diseases
JP5780430B2 (ja) 2009-01-17 2015-09-16 アドヴェリオ・ファーマ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 勃起不全の処置用のＰＤＥ５阻害剤と組み合わせたｓＧＣ刺激剤またはｓＧＣ活性化剤
WO2010099054A2 (en) 2009-02-26 2010-09-02 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
HRP20151187T1 (hr) 2010-02-05 2015-12-04 Adverio Pharma Gmbh sGC STIMULATORI ILI sGC AKTIVATORI SAMOSTALNO I U KOMBINACIJI S INHBITORIMA PDE5 ZA LIJEÄŚENJE CISTIÄŚNE FIBROZE
WO2011095553A1 (en) 2010-02-05 2011-08-11 Bayer Schering Pharma Aktiengesellschaft Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction
MY170094A (en) 2010-05-26 2019-07-05 Adverio Pharma Gmbh The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of systemic sclerosis (ssc).
US20130158028A1 (en) 2010-06-25 2013-06-20 Bayer Intellectual Property Gmbh Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes
EP2632551B1 (en) 2010-10-28 2016-07-06 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
WO2012122340A1 (en) * 2011-03-10 2012-09-13 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
US8815857B2 (en) 2011-08-12 2014-08-26 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
EP2594270A3 (en) 2011-11-18 2013-07-31 BIP Patents The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)
MA37891B1 (fr) 2012-09-07 2018-05-31 Boehringer Ingelheim Int Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
WO2015095515A1 (en) 2013-12-20 2015-06-25 Novartis Ag Sgc activators for the treatment of glaucoma

Also Published As

Publication number Publication date
PH12017500111A1 (en) 2017-05-29
CN106459017A (zh) 2017-02-22
JP2017521457A (ja) 2017-08-03
AU2015292833A1 (en) 2016-12-22
US9353090B2 (en) 2016-05-31
TWI711615B (zh) 2020-12-01
CA2955937A1 (en) 2016-01-28
CO2017000438A2 (es) 2017-08-31
EA032972B1 (ru) 2019-08-30
PE20170249A1 (es) 2017-04-05
HUE049231T2 (hu) 2020-09-28
MX378717B (es) 2025-03-10
MX2017000926A (es) 2017-05-04
CL2017000071A1 (es) 2017-06-30
EP3172202B1 (en) 2020-01-29
PL3172202T3 (pl) 2020-07-13
DK3172202T3 (da) 2020-04-27
SG11201700507XA (en) 2017-02-27
ES2784477T3 (es) 2020-09-28
AP2016009615A0 (en) 2016-12-31
EP3172202A1 (en) 2017-05-31
US20160024059A1 (en) 2016-01-28
UY36226A (es) 2016-01-29
KR20170035993A (ko) 2017-03-31
JP6602840B2 (ja) 2019-11-06
CN106459017B (zh) 2020-07-17
SG10201806565SA (en) 2018-08-30
WO2016014463A1 (en) 2016-01-28
AR101265A1 (es) 2016-12-07
PT3172202T (pt) 2020-05-06
TW201617340A (zh) 2016-05-16
AU2015292833B2 (en) 2019-11-28
EA201790246A1 (ru) 2017-07-31
BR112017000943A2 (pt) 2017-11-14

Similar Documents

Publication Publication Date Title
IL249587A0 (en) Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
SG10202110874TA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
IL247970A0 (en) Quinoline history as smo inhibitors
HUE041926T2 (hu) IRAK4 inhibitor biciklusos heterociklilszármazékok
IL254898A0 (en) History of quinolines as tam rtk inhibitors
HUE040274T2 (hu) Heteroarilamidok a proteinaggregáció inhibitoraiként
DK3201206T3 (da) Borsyrederivater
HUE050974T2 (hu) Eljárás pirimidinszulfamid-származékok elõállítására
HUE042064T2 (hu) Pirrolidinon-származékok MetAP-2 inhibitorokként
IL246345A0 (en) History of 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid as neprilysin inhibitors
FR3023290B1 (fr) Derives de flavaglines
DK3143018T3 (da) Carboxamidderivater
PL3200786T3 (pl) Zastosowanie pochodnych pirydylowych o skondensowanym układzie bicyklicznym jako inhibitorów fgfr4
PT3134396T (pt) Derivados de amino piridina como inibidores da fosfatidilinositol 3-quinase
LT3319970T (lt) Pirido-oksazinono dariniai kaip tnap inhibitoriai
HUE042119T2 (hu) Aminoészter-származékok
IL266121A (en) A history of metamorphosed quinoxaline as an inhibitor of pfkfb
IL251099A0 (en) A salt of phenylglycine methyl ester
DK3283066T3 (da) 4-Phenylsmørsyrederivater
HK1232872A1 (en) Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
TH1501006974A (th) อนุพันธ์เฮเทอโรไซคลิค
TH1501004620A (th) เฮทเทอโรไซคลิก เอไมด์ ในรูปสารยับยั้งไคเนส
TH1601003581A (th) อนุพันธ์เฮทเทอโรแอริลบิวทาโนอิกแอซิด ซึ่งเป็นสารยับยั้ง lta4h
TH1501007053A (th) เอสเทอร์ของกรดโอลิโก-ไฮดรอกซิคาร์บอกซิลิกและการใช้ของมัน